[Indapamide in the treatment of hypertension in diabetes]

The authors treated 20 diabetics (14 men and 6 women) in an open clinical trial with indapamide (Arifon, Zorka Co.) for a period of three months, using a morning dose of 2.5 mg. In 10 patients with hypertension stage I in all normalization of the systolic pressure below 18.6 kPa and diastolic pressure below 12 kPa was achieved. Treatment of patients with hypertension stage II was not adequate in 6 patients. In the course of treatment metabolic compensation of diabetes (type 1 or type 2) did not deteriorate. No changes in the blood lipid spectrum and mineral metabolism were recorded. Indapamide is an antihypertensive drug suitable for treatment of mild hypertension in diabetics as monotherapy.